A venture capital firm that was established in 2015 and is headquartered in Western Europe. The firm will consider pre-seed investments but is primarily looking to participate in the Seed to Series A financings of early-stage companies with typical pre-money valuation usually between USD 5 million and USD 30 million. Average ticket size is USD 0.5 million. The firm currently participates in equity investments as well as convertible debt. The firm historically has made around ten new investments per year. The firm is focused on partnering with companies based in Western Europe but will consider global opportunities.
The firm is primarily interested in investing in companies in the medical technology and digital health sectors but will also consider those in the wearables and diagnostics sector as well. The firm is open to all modalities within the medical technology and digital health sectors but prefers diagnostic companies to be focused on devices rather than genomics or in vitro diagnostics. The firm will not consider investments in biotech or pharma companies. The firm prefers to invest in pre-market technologies with some proof of pre-clinical data available and will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm will consider companies across all disease indications but prefers to avoid complex disease indications such as the oncology space.
The firm is open to working with both inexperienced and experienced management teams. The firm looks to work with management teams that are efficient and work well together. The firm will sometimes take a board seat as determined on a case-by-case basis. The firm normally prefers to co-invest but will occasionally take a lead role in investments.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Early-Stage Venture Fund Formed by Leading University Alumni Invests in All Life Science Sectors, Focusing on Seed to Series A Rounds
An early stage fund founded by a group of alumni from a leading university is based in the USA. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.
The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based Firm Explores Investment and Strategic Partnership Opportunities That Align With Their Existing Products, Including Surgical Robotics
A firm based in the USA works with early stage startups using a variety of structures, including co-development, equity investments, licensing, and M&A. The firm works with startups that have a strategic alignment with their firm and/or fit their parameters for a venture investment. The firm is a multi-stage investor and is interested in new technologies worldwide.
The firm is interested in new technologies that are strategically related to the company’s existing robotics surgery systems. The firm is interested in instruments and accessories that can be attached or used with its robotic for use in minimally invasive surgical and endobronchial procedures, and in technologies that improve the dexterity, precision and safety of surgical robotics. Technologies that support the vision/scope abilities of the firm’s systems are an area of interest, including 3DHD technologies, imaging agents and devices that can be used in conjunction with robotics, and non-imaging tools such as AI that enhances surgical vision. Additionally, the firm is interested in devices and digital health technologies used by surgeons and hospitals, such as technologies to improve workflow for surgical suites or which provide surgeons with additional data. The firm is interested in any indication area in which robotics is applicable; cancer diagnosis and treatment is a core area of interest. The firm is interested in working with companies at any stage of development.
The firm Surgical is flexible regarding different types of partnership, and is focused on achieving strategic alignment with their partners. The firm typically works alongside the partner to achieve integration between their existing technology and the new technology. While the firm will consider very early stage opportunities, typically a working prototype or demo is required for assessment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Leading Biopharmaceutical Seeks Licensing and Collaboration Opportunities For China and Global Market in Oncology, CNS, Autoimmune Disease, and More
One of the leading fully integrated biopharmaceutical companies in China has established three integrated R&D centers, with locations in USA and China. The firm has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes. The firm is actively seeking for licensing/collaboration on development candidates with first-in-class or best-in-class potentials, and commercial products with substantial market opportunities in China and worldwide.
The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease, as well as a technology platform in Cell Therapy.
The firm is looking for companies with capacity and experience in implementing R&D plans. The firm is interested in assets from the US, Europe or other countries, and intends to introduce the product to the Chinese market.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Panels at RESI JPM San Francisco
By Rory McCann, Director of Marketing & Conference Producer, LSN
RESI JPM San Francisco, January 10-12, 2023 is Life Science Nation (LSN)’s next hybrid event, taking place during J.P. Morgan Healthcare week, taking advantage of the convergence of life science and healthcare leaders to San Francisco. RESI, as a powerful early-stage deal-making vehicle, is the perfect option for fundraising executives seeking connection with investors and licensing partners in 2023. One of the many meaningful methods RESI uses to connect entrepreneurs with potential partners is through investor panels discussing the latest industry trends, with valuable insights as to standing out to and communicating with potential partners.
A recent RESI Boston attendee praised the panels she attended, saying that by simply attending a panel, she was able to learn enough about an investor to touch base and book a meeting onsite that day. Don’t miss out on the countless opportunities RESI San JPM Francisco panels have to fast-track an introduction and lead to meaningful conversations. Check out the panel lineup below and sign up for Digital RESI November (virtual partnering only) with RESI San JPM Francisco and save $1,000 by tomorrow!
Tuesday, January 10, 8:00 – 8:50 AM PST
Angels and Family Offices
How Do Family Offices & Angels View Seed & Series A Rounds?
Angel investors are a mainstay in the earliest financing rounds, and many consider Family Offices as the holy grail of investors. These groups share many similarities, and can work in synergy to help their portfolio companies advance. This panel will cover topics such as:
- What are the similarities and differences between Angels and Family Offices?
- What are the benefits of working with each group?
- How does investing personal money change the way Angels and Family Offices act from the traditional VC?
A startup looks to many different kinds of investors when fundraising, and understanding the fundamental differences between groups can improve the success of their approach. Angels and Family Offices frequently invest early on, and can shape the way a company develops. Panelists will discuss how best to approach them and engage their interest.
Tuesday, January 10, 9:00 – 9:50 AM PST
Big Pharma
Strategies for Preclinical & Early Clinical Assets
In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This panel brings together speakers from various big pharma companies to discuss topics such as:
- How big pharma sources assets
- The evaluation and investment process
- Key factors of interest
- How early-stage big pharma is willing to look
These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.
Tuesday, January 10, 10:00 – 10:50 AM PST
Pitching Your AI to Investors
Strategies for Standing Out
AI is embedded in the tech of many life science startups, but are they utilizing it to stand out to investors? Hear from life science and tech investors on how early-stage founders can pitch their AI technology effectively. The right connection can start with a strong first impression, so learn how to bring your tech from pitch to partnership.
Tuesday, January 10, 11:00 – 11:50 AM PST
Pediatrics
Advancing Treatments for Pediatric Patients
Since 2015, the US regulatory, public/private payor, and clinical research environments have implemented sweeping changes to the policies and requirements governing healthcare innovation targeting the pediatric patient population. Despite these changes, funding for pediatric innovation remains exponentially lower relative to the nature of the commitments being made to adult indications, especially troubling in light of nearly 40% of the world’s population will be under the age of 21, yet less
than 15% of all healthcare investment is targeting pediatric indications. This panel will explore several topics including:
- What are the specific gaps in pediatric patient engagement?
- How and why are current novel treatments under development superior to historic care options?
- What are the challenges that impact the efficiency, effectiveness, and successful commercialization of scientific innovations targeting the pediatric patient population?
- What changes need to be made to incentivize and motivate global healthcare manufacturers to increase their pediatric healthcare R&D budgets respectively?
Panelists will discuss topics relevant to all areas of pediatric care and the importance of addressing an underserved population, and how improvements to pediatric care can save long-term costs for the healthcare industry long after these patients reach adulthood.
Tuesday, January 10, 1:00 – 1:50 PM PST
Asia Cross Border
Building Global Partnerships
These days, seeking capital from Asia-headquartered investors, pharmaceuticals, and other strategic partners may seem like nothing new. Many groups continue to expand into geographies outside of Asia to set up new offices, establishing open innovation departments, etc. However, companies based in the USA, Europe, and other parts of the world without any proper connection to Asia still find themselves struggling to engage with the right groups. This panel will discuss the following topics and more:
- How are Asian markets and regulatory hurdles different from those of the USA/Europe?
- What do cross-border investors seek in companies outside of Asia? How are they similar or different to their viewpoint on domestic companies?
- How has COVID positively or negatively impacted the decision making process?
- Aside from the effects of COVID on the industry, will cross-border investment activities continue to increase?
- What are some common mistakes investors see from entrepreneurs, and how can they be avoided?
Panelists will discuss how they have been evaluating opportunities in the midst of the COVID pandemic and what the future holds for cross-border activities in the industry. Panelists will also uncover general topics such as navigating the Asian market and the regulatory challenges associated with market entry, how to approach Asian investors and strategic groups, and more.
Tuesday, January 10, 2:00 – 2:50 PM PST
Longevity Investment
Aging Innovation for a Better Future
This panel will feature investors that focus on longevity. Learn about their investment preferences and how they evaluate and manage their relationships with their early-stage portfolio and prospects in this specific market. Hear from active age-tech experts on their predictions for the future of this sector.
Tuesday, January 10, 3:00 – 3:50 PM PST
Medtech Strategics
Large Corporations Seeking External Innovation in the MedTech Space
In the medical technology sector, major corporations are increasingly looking to external startups and inventors for innovative new technologies. In addition to traditional M&A, these major strategic players are exploring innovative strategies to partner with early stage startups, and our speakers will explore topics such as:
- How do major corporations find new device technologies that are a fit for their pipelines?
- What can an early stage startup do to find the right partner?
- How do partnerships work, and what conditions might a major partner have?
- What kind of technical and commercial validation will be required to secure a partnership?
- The panelists will explore these topics with reference to the technology areas that they are looking at for their future pipelines.
Tuesday, January 10, 4:00 – 4:50 PM PST
Corporate VC
The Changing Landscape & New Opportunities
Corporate venture capital firms are an important source of capital for early-stage companies. Many major pharmaceuticals and large corporations have set up a corporate investment arm to identify early-stage companies. Strategically and financially driven in varying degrees, the implications of working with CVCs are huge, as the resources, network, and guidance provided by the CVC and the associated parent company are incredibly valuable to an entrepreneur who is actively growing their business.
This panel will discuss the following topics and more:
- How are CVCs different from traditional VCs?
- How strategically vs. financially are CVCs driven, and how does this affect their decision-making process?
- How closely does the CVC communicate with the parent company?
- What does working with a CVC entail?
Panelists will discuss each of their investment mandates and how they relate to corporate interests, and how they have been sourcing opportunities during COVID. Panelists may also explore current trending areas of interest, and what they see as emerging fields in the near future.
Free Fall Webinars – Navigating Partnering Events like a Pro
By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN
Partnering events can be the best ways to engage with potential investors and strategic partners in the early-stage arena. Life Science Nation is offering a series of free webinars to help life science and healthcare entrepreneurs make the most out of partnering events, such as Digital RESI, November 15-16, 2022 and RESI San Francisco, January 10-12, 2023. These webinars offer tactical advice to early-stage companies on how to maximize outcomes when attending conferences like RESI and moving connections beyond the event. Attend these complimentary webinars and save $1,000 on a special bundle deal for Digital RESI November and RESI San Francisco by October 21.
Register below to join these complimentary online sessions:
October 20, 1:30 PM EDT – Sign-up
The Best Partnering Practice: Virtually vs. Face-to-Face
Greg Mannix, Vice President, International Business Development, General Manager, Europe, Life Science Nation
Partnering in the digital world of the past few years has taught us all new skills. Now that in-person events have returned—often with a “hybrid” component—there are some key tactics you should keep in mind to get the best results.
November 1, 1:00 PM EDT – Sign-up
Partnering Live Tutorial
Antoinette Lowre, Manager, Business Development, Life Science Nation
This partnering tutorial covers basic functions of the RESI partnering platform, how to set up your profile, how to search for investors/strategic partners, how to book and request meetings and what your outreach strategy should look like when requesting meetings.
November 2, 12:00 PM EDT – Sign-up
Pitching at the Biggest Partnering Event of the Year (Session 1)
Karen Deyo, Director, Investor Research, Israel Business Development, Life Science Nation
Alexander Vassallo, Manager, Business Development, Life Science Nation
As RESI returns to JPM week next January, the biggest partnering event of the year for the life sciences industry, so does the Innovator’s Pitch Challenge (IPC). Being able to deliver a powerful and compelling pitch to portray why your company’s unique technology should be an investor’s top interest can help make this week potentially one of the most productive of the year. Join Karen and Alex on this webinar to discuss making the most of your pitch opportunity at JPM week next year!
November 22, 11:00 AM EDT – Sign-up
Pitching at the Biggest Partnering Event of the Year (Session 2)
Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
Claire Jeong, Chief Conference Officer, Vice President, Investor Research, Asia Business Development, Life Science Nation
As RESI returns to JPM week next January, the biggest partnering event of the year for the life sciences industry, so does the Innovator’s Pitch Challenge (IPC). Being able to deliver a powerful and compelling pitch to portray why your company’s unique technology should be an investor’s top interest can help make this week potentially one of the most productive of the year. Join Karen and Alex on this webinar to discuss making the most of your pitch opportunity at JPM week next year!
RESI Sponsorship to Expand Reach and Optimize Impact
By Antoinette Lowre, Manager of Business Development, LSN
Life Science Nation (LSN)’s RESI conference series is one of the only early-stage focused partnering experiences in the life science and healthcare ecosystem. All players use RESI to rally their partnership and fundraising goals. Sponsoring RESI is the fast-track to reaching these goals.
Benefits of sponsoring a RESI conference include increasing global brand and reach, sourcing, vetting and developing key relationships with your target audience, showcase your product and services through workshops and panels, and use our one-of-a-kind match-based partnering platform to connect with strategic partners and build relationships.
Check out our Sponsorship Brochure to meet your goals and reach your intended audience. Contact your BD rep to learn more on how to sponsor and gain visibility at Digital RESI, November 15-16, 2022 and RESI San Francisco, January 10-12, 2023
Next Phase Newsletter 